![Stephen Willard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stephen Willard
Chief Executive Officer at
LONGEVEROPAR
Net worth: 540 948 $ as of 2026-07-30
Profile
Stephen H.
Willard is Chief Executive Officer & Director at Longeveron, Inc. since 2026.
Mr. Willard is Director at Global Life Technologies Corp.
Mr. Willard is Director at The National Science Board since 2018.
Former roles include Chief Executive Officer & Director at Cellphire, Inc. from 2013 to 2021; Chief Executive Officer & Secretary at NRX Pharmaceuticals, Inc. in 2024; Executive Director at Nozin, Inc. from 2021 to 2022; Non-Executive Chairman at Flamel Technologies SA from 2012 to 2014; Independent Director at E*TRADE Financial Corp.
from 2012 to 2014; Director at E*TRADE Bank from 2000 to 2014; Director at ETB Holdings, Inc. in 2005; Associate Director-Resolutions at Federal Deposit Insurance Corp.
from 1991 to 1994; Chief Executive Officer at Icapath, Inc.; and President at Flamel Technologies, Inc. Education includes graduate degree from Yale University in 1985 and undergraduate degree from Williams College in 1982.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-30 | 771,681 ( 2.56% ) | 540 948 $ | 2026-07-30 |
Stephen Willard active positions
| Companies | Position | Start |
|---|---|---|
| LONGEVEROPAR | Chief Executive Officer | 2026-02-10 |
Global Life Technologies Corp.
 Global Life Technologies Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Director/Board Member | - |
The National Science Board | Director/Board Member | 2017-12-31 |
Former positions of Stephen Willard
| Companies | Position | End |
|---|---|---|
Icapath, Inc.
 Icapath, Inc. Miscellaneous Commercial ServicesCommercial Services Develops drug delivery technology that combines PLGA nanoparticles | Chief Executive Officer | 2025-09-30 |
| NRX PHARMACEUTICALS, INC. | Chief Executive Officer | 2024-10-10 |
Cellphire, Inc.
 Cellphire, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that develops platelet-derived therapeutics | Chief Executive Officer | 2021-02-28 |
Flamel Technologies SA
 Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Chairman | 2014-07-01 |
Training of Stephen Willard
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
77
1st degree connections
14
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
E*TRADE Financial Corp.
 E*TRADE Financial Corp. Investment Banks/BrokersFinance Provides online stock brokerage and investing services | Finance |
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
E*TRADE Bank
 E*TRADE Bank Regional BanksFinance Provides banking services | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Williams College
 Williams College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Federal Deposit Insurance Corp.
 Federal Deposit Insurance Corp. Insurance Brokers/ServicesFinance Operates as an insurance agency | Finance |
ETB Holdings, Inc.
 ETB Holdings, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Flamel Technologies, Inc. | |
The National Science Board | |
Cellphire, Inc.
Cellphire, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that develops platelet-derived therapeutics | Commercial Services |
Longeveron, Inc.
 Longeveron, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops cellular therapies for aging-related and life-threatening conditions | Health Technology |
Global Life Technologies Corp.
Global Life Technologies Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
NRX Pharmaceuticals, Inc.
 NRX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a molecule pharmaceutical company | Health Technology |
Icapath, Inc.
Icapath, Inc. Miscellaneous Commercial ServicesCommercial Services Develops drug delivery technology that combines PLGA nanoparticles | Commercial Services |
- Stock Market
- Insiders
- Stephen Willard
